Source: Annual Congress 2004 - Descriptive epidemiology of sarcoidosis, tuberculosis and pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. D. Zhogolev, P. I. Ogarkov, K. D. Jogolev (St Petersburg, Russia). Use of the pneumococcal 23-valent polysaccharide vaccine in recruits in Russia. Eur Respir J 2004; 24: Suppl. 48, 2273

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population Source: Eur Respir J 2016; 48: 1492-1496 Year: 2016 Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia Source: Eur Respir J 2015; 45: 1632-1641 Year: 2015 Clinical evolution of patients with COPD after administration of 23-valent pneumococcal capsular polysacharide vaccine (PCPV) Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 673s Year: 2005 Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 Pneumococcal vaccination: current and future issues Source: Eur Respir J 2001; 18: 184-195 Year: 2001 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden Source: Eur Respir J 2016; 47: 1208-1218 Year: 2016 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Influenza and pneumococcal vaccination Source: International Congress 2017 – State of the art session: "Respiratory infections" Year: 2017 Pneumococcal vaccination Source: Eur Respir J 2005; 26: 982-983 Year: 2005 Assessment of medical undergraduates’ relation to pneumococcal conjugate vaccine use Source: Virtual Congress 2021 – Medical education in respiratory medicine Year: 2021 Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Source: Eur Respir J 2004; 23: 363-368 Year: 2004